Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Cell Chemical Biology
|
February 11, 2023
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation
Scott C Rosenberg, Frances Shanahan, Sayumi Yamazoe, et al.
Plos Biology
|
September 17, 2019
MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
Lieselotte Vande Walle, Irma B Stowe, Pavel Šácha, et al.
Plos Biology
|
October 17, 2019
Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
Lieselotte Vande Walle, Irma B Stowe, Pavel Šácha, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 26, 2012
Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase
Steven T Staben, Nicole Blaquiere, Vickie Tsui, et al.
Journal of Medicinal Chemistry
|
October 12, 2011
Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform
Timothy P Heffron, Binqing Wei, Alan Olivero, et al.
Cell Chemical Biology
|
May 16, 2025
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
Anna Shemorry, Willem den Besten, Melinda M Mulvihill, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 4, 2011
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
Steven T Staben, Michael Siu, Richard Goldsmith, et al.
Journal of Medicinal Chemistry
|
January 18, 2014
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors
Steven T Staben, Jianwen A Feng, Karen Lyle, et al.
Journal of Medicinal Chemistry
|
November 15, 2021
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors
Dennis X Hu, Snahel Patel, Huifen Chen, et al.
Biochemistry
|
January 5, 2022
A Multifaceted Hit-Finding Approach Reveals Novel LC3 Family Ligands
Micah Steffek, Elizabeth Helgason, Nataliya Popovych, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Cell Chemical Biology
|
February 11, 2023
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation
Scott C Rosenberg, Frances Shanahan, Sayumi Yamazoe, et al.
Plos Biology
|
September 17, 2019
MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
Lieselotte Vande Walle, Irma B Stowe, Pavel Šácha, et al.
Plos Biology
|
October 17, 2019
Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
Lieselotte Vande Walle, Irma B Stowe, Pavel Šácha, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 26, 2012
Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase
Steven T Staben, Nicole Blaquiere, Vickie Tsui, et al.
Journal of Medicinal Chemistry
|
October 12, 2011
Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform
Timothy P Heffron, Binqing Wei, Alan Olivero, et al.
Cell Chemical Biology
|
May 16, 2025
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
Anna Shemorry, Willem den Besten, Melinda M Mulvihill, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 4, 2011
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
Steven T Staben, Michael Siu, Richard Goldsmith, et al.
Journal of Medicinal Chemistry
|
January 18, 2014
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors
Steven T Staben, Jianwen A Feng, Karen Lyle, et al.
Journal of Medicinal Chemistry
|
November 15, 2021
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors
Dennis X Hu, Snahel Patel, Huifen Chen, et al.
Biochemistry
|
January 5, 2022
A Multifaceted Hit-Finding Approach Reveals Novel LC3 Family Ligands
Micah Steffek, Elizabeth Helgason, Nataliya Popovych, et al.
Page
of 5